Vaxxinity (VAXX) News Today $0.0002 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brain healthOctober 24, 2024 | newsweek.comTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockApril 19, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 28, 2024 | globenewswire.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | investorplace.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 27, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024March 7, 2024 | globenewswire.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | finance.yahoo.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 13, 2024 | finance.yahoo.comVaxxinity (NASDAQ:VAXX) Shares Down 2.2% Vaxxinity (NASDAQ:VAXX) Trading Down 2.2%February 8, 2024 | marketbeat.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 30, 2024 | finance.yahoo.comVaxxinity & UCF to Collaborate on Space Medicine ResearchJanuary 19, 2024 | finance.yahoo.comVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaJanuary 18, 2024 | finance.yahoo.comVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceJanuary 3, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityDecember 12, 2023 | finance.yahoo.comAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And OthersNovember 21, 2023 | markets.businessinsider.comSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successNovember 20, 2023 | foxnews.comResearchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 20, 2023 | msn.comVaxxinity to Present at Upcoming November Medical and Investor ConferencesNovember 13, 2023 | finance.yahoo.comVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 8, 2023 | finance.yahoo.comPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declineOctober 10, 2023 | finance.yahoo.comMovers Lab Fund I. Lp Prime Sells 25,089 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) StockVaxxinity, Inc. (NASDAQ:VAXX - Get Free Report) major shareholder Movers Lab Fund I. Lp Prime sold 25,089 shares of the firm's stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $1.67, for a total value of $41,898.63. Following the completion of the transaction, the insider now owns 8,713,663 shares in the company, valued at approximately $14,551,817.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.September 8, 2023 | marketbeat.comDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)September 7, 2023 | finance.yahoo.comVaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s TreatmentAugust 11, 2023 | finance.yahoo.comVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseAugust 10, 2023 | finance.yahoo.comVaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comVaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorJuly 28, 2023 | finance.yahoo.comVaxxinity Appoints Dr. Peter Powchik as Global Scientific DirectorJuly 28, 2023 | finance.yahoo.comLincoln National Corp Invests $93,000 in Vaxxinity, Inc. (NASDAQ:VAXX)Lincoln National Corp purchased a new stake in Vaxxinity, Inc. (NASDAQ:VAXX - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 41,070 shares of the company's stock, valued at approximatelyJuly 28, 2023 | marketbeat.comPromising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s PatientsJuly 17, 2023 | finance.yahoo.comVaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s PatientsJuly 17, 2023 | finance.yahoo.comMcAdam LLC Buys New Stake in Vaxxinity, Inc. (NASDAQ:VAXX)McAdam LLC bought a new stake in Vaxxinity, Inc. (NASDAQ:VAXX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 46,324 shares of the company's stock, valued at approximatelyJuly 9, 2023 | marketbeat.comPositive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s DiseaseJune 22, 2023 | finance.yahoo.comVaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine TrialJune 22, 2023 | finance.yahoo.comVaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s DiseaseJune 22, 2023 | finance.yahoo.comVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | finance.yahoo.comVaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last weekMay 3, 2023 | finance.yahoo.comWeekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro RecapApril 24, 2023 | finance.yahoo.comVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in AprilMarch 28, 2023 | finance.yahoo.comVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdatesMarch 27, 2023 | finance.yahoo.comVaxxinity Joins TransCelerate Research and Development ConsortiumMarch 21, 2023 | finance.yahoo.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat HypercholesterolemiaMarch 20, 2023 | finance.yahoo.com Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address “This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in… >> YES! Send Me My FREE Gold Guide! VAXX Media Mentions By Week VAXX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VAXX News Sentiment▼0.000.49▲Average Medical News Sentiment VAXX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VAXX Articles This Week▼00▲VAXX Articles Average Week Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Navidea Biopharmaceuticals News Today Ampio Pharmaceuticals News Today Statera Biopharma News Today eFFECTOR Therapeutics News Today Alvotech News Today biote News Today BriaCell Therapeutics News Today Clever Leaves News Today Fortress Biotech News Today GeoVax Labs News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VAXX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts